Kura Oncology (KURA) Equity Average (2011 - 2026)

Kura Oncology (KURA) has 16 years of Equity Average data on file, last reported at $141.0 million in Q1 2026.

• Equity Average for Q1 2026 came in at $141.0 million, down 63.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $141.0 million (down 63.75% YoY), and the FY2025 annual result was $293.9 million, down 27.52% from the prior year.
• Equity Average retreated to $141.0 million in Q1 2026 per KURA's latest filing, from $208.3 million in the prior quarter.
• Over five years, Equity Average peaked at $491.4 million in Q1 2022 and troughed at $141.0 million in Q1 2026.
• A 5-year average of $391.2 million and a median of $419.9 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2026: Equity Average climbed 13.6% in 2024, then slumped 63.75% in 2026.
• A 5-year view of Equity Average shows it stood at $419.9 million in 2022, then slipped by 1.51% to $413.6 million in 2023, then advanced by 1.23% to $418.7 million in 2024, then plunged by 50.24% to $208.3 million in 2025, then plunged by 32.32% to $141.0 million in 2026.
• Business Quant data shows KURA's Equity Average at $141.0 million in Q1 2026, $208.3 million in Q4 2025, and $274.0 million in Q3 2025.